These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25797461)

  • 1. Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer.
    Bahig H; Fortin B; Alizadeh M; Lambert L; Filion E; Guertin L; Ayad T; Christopoulos A; Bissada E; Soulières D; Gaba Idiamey F; Nguyen-Tan PF
    Oral Oncol; 2015 May; 51(5):521-8. PubMed ID: 25797461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
    Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ
    J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.
    Biagioli MC; Harvey M; Roman E; Raez LE; Wolfson AH; Mutyala S; Han HS; Markoe A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1067-73. PubMed ID: 17967302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
    Brizel DM; Albers ME; Fisher SR; Scher RL; Richtsmeier WJ; Hars V; George SL; Huang AT; Prosnitz LR
    N Engl J Med; 1998 Jun; 338(25):1798-804. PubMed ID: 9632446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer.
    Espeli V; Zucca E; Ghielmini M; Giannini O; Salatino A; Martucci F; Richetti A
    Oral Oncol; 2012 Mar; 48(3):266-71. PubMed ID: 22079100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
    Bernier J; Domenge C; Ozsahin M; Matuszewska K; Lefèbvre JL; Greiner RH; Giralt J; Maingon P; Rolland F; Bolla M; Cognetti F; Bourhis J; Kirkpatrick A; van Glabbeke M;
    N Engl J Med; 2004 May; 350(19):1945-52. PubMed ID: 15128894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer.
    Watkins JM; Zauls AJ; Wahlquist AH; Shirai K; Garrett-Mayer E; Gillespie MB; Day TA; Sharma AK
    Laryngoscope; 2010 Feb; 120(2):236-42. PubMed ID: 19950378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin.
    Ishizuka M; Fujimoto Y; Itoh Y; Kitagawa K; Sano M; Miyagawa Y; Ando A; Hiramatsu M; Hirasawa N; Ishihara S; Nakashima T; Yamada K
    Jpn J Clin Oncol; 2011 Aug; 41(8):973-9. PubMed ID: 21693483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.
    Caudell JJ; Sawrie SM; Spencer SA; Desmond RA; Carroll WR; Peters GE; Nabell LM; Meredith RF; Bonner JA
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):676-81. PubMed ID: 18355979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of T4 locally advanced head and neck cancers with soft tissue invasion or bone and cartilage invasion.
    Do L; Puthawala A; Syed N; Azawi S; Williams R; Vora N
    Am J Clin Oncol; 2009 Oct; 32(5):477-82. PubMed ID: 19506456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment prognostic factors influencing distant metastasis-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
    Jeremić B; Miličić B
    Am J Clin Oncol; 2009 Oct; 32(5):483-7. PubMed ID: 19506455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer.
    Givens DJ; Karnell LH; Gupta AK; Clamon GH; Pagedar NA; Chang KE; Van Daele DJ; Funk GF
    Arch Otolaryngol Head Neck Surg; 2009 Dec; 135(12):1209-17. PubMed ID: 20026818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
    Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.